Dendritic cells (DC) engineered in vitro by DNA encoding OVAhsp70 and IL-15 up-regulated their expressions of CD80, CD86, CCR7 and IL-15Ra and promoted their productions of IL-6, IL-12 and TNF-a. Transcriptional IL-15-directed in vivo DC targeting DNA vaccine encoding OVAhsp70 elicited long-lasting Th1 and CTL responses and anti-B16OVA activity. CD8T cell-mediated primary tumor protection was abrogated by DC or CD4T cell depletion during the induction phase of immune responses. However, CD4T cell depletion during immunization did not impair CD8T cell-dependent long-lasting tumor protection.
Introduction
DNA vaccines are safe, relatively inexpensive and effective in eliciting innate and adaptive immune responses and protective immunity. [1] [2] [3] DNA vaccination, therefore, is a practical and promising strategy aimed at developing effective vaccines against tumors and infectious diseases. [1] [2] [3] Weak immunogenicity of DNA vaccines is a major obstacle to current DNA vaccine development and may be responsible for the ineffective vaccination in human beings. [1] [2] [3] Many strategies have been designed and tested to overcome this problem including administration of DNA encoding cytokines, chemokines, costimulatory molecules, survival factor or helper Ag, [4] [5] [6] [7] [8] injection of mAb, 9 addition of chemical adjuvant, 10 enhancement of Ag expression, 11 improvement of DNA delivery 12 and modification of Ag. 3, 13 Dendritic cells (DC) are essential in initiating, programming and regulating Ag-specific T-cell immunity and the key target of DNA vaccines. 5, [14] [15] [16] [17] [18] [19] [20] DNA vaccine encoding single-chain antibodies (through receptor CD205) to target Ag to DC enhances its potency. 21, 22 Targeting Ag to DC alone without providing proper DC activation signaling can result in tolerance not immunity. 23, 24 Thus, DC targeting strategies should include means to activate DC. Although DNA self-triggering and some receptor (such as FcR, TLR) triggering may provide some DC activation stimuli, [25] [26] [27] [28] these stimuli were usually insufficient for optimal DC activation. Strong Ag-specific CD4 and CD8T cell responses are critical to reject tumors and chronic infectious diseases. [1] [2] [3] 13, 22 To achieve this, DNA vaccines need to target DC for Ag processing and presentation through MHC class I and II pathways and optimal DC activation. In particular, DNA vaccines encoding Ag fused to hsp70 (Aghsp70) elicited better Ag-specific CD4 and CD8T cell responses and antitumor immunity. [29] [30] [31] The mechanisms behind the observations were linked to target Ag to DC (through CD40 and LOX-1) and activate DC (through CD40). [30] [31] [32] [33] [34] IL-15 is a critical cytokine for the development and function of innate and adaptive immune cells. 35 DNAderived IL-15 has been coadministrated as an adjuvant to enhance the potency of DNA vaccines encoding Ag. 36, 37 Accumulated data have indicated that DC-derived IL-15 is necessary for the induction and maintenance of CD8T cell responses and may be a signal for DC activation to promote immunity. 35, [38] [39] [40] Whether transcriptional IL-15-directed in vivo DC targeting can enhance the efficacy of a DNA vaccine has not yet been proven.
In this study, we constructed a novel DNA vaccine with the ubiquitous expression and secretion of a fusion Ag (Aghsp70) and the DC-specific expression and secretion of an optimized human IL-15 (IL-15). 36 We tested the ability of DC-derived IL-15 to improve DC activation, cellular and humoral immune responses and tumor protection in B16 melanoma with a model Ag (OVA) or self/tumor Ag (TRP2). We also examined the mechanisms underlying this novel DNA vaccine strategy.
Results

Construction and expression of a novel DNA vaccine
We designed a novel DNA vaccine with CMV promoterdriven ubiquitous expression of Aghsp70 and CD11c promoter-driven DC-specific expression of optimized IL-15 ( Figure 1a ). Bone marrow-derived CD11c + DC or 293T cells were transfected with CMV-OVAhsp70-CD11c-IL-15, CMV-OVAhsp70-CD11c or CMV-CD11c DNA and continually cultured for 48 h. OVAhsp70 was detected in the lysates of CD11c + DC or culture supernatants of 293T cells transfected with CMV-OVAhsp70-CD11c-IL-15 and CMV-OVAhsp70-CD11c, but not CMV-CD11c DNA (Figure 1b) . (Owing to the interference by fetal bovine serum (FBS), secreted OVAhsp70 was detected in FBS-free culture supernatants of transfected 293T cells, but not in FBS-containing culture supernatants of transfected DC.) Furthermore, CD11c
+ DC transfected by CMV-OVAhsp70-CD11c-IL-15 DNA secreted significant IL-15 ( Figure 1c ). The data suggest that OVAhsp70 and IL-15 are expressed well by CD11c + DC after DNA transfection.
Transcriptional IL-15-directed DC targeting improves Aghsp70-enginerred DC activation in vitro
The function of Aghsp70 was linked to activate DC. 34 To determine whether transcriptional IL-15-directed DC targeting can further improve Aghsp70-engineered DC activation, cultured CD11c + DC were transfected with CMV-OVAhsp70-CD11c-IL-15 DNA or related control vectors. Day 3 post transfection, DC and culture supernatants were harvested and analyzed by flow cytomerty and ELISA, respectively, to monitor DC phenotypes and cytokines. CMV-OVAhsp70-CD11c-IL-15-engineered DC not only markedly improved expressions of CD80, CD86, CCR7 and IL-15Ra (Figure 2a ), but also dramatically increased the productions of IL-6, IL-12 and TNF-a (Figure 2b ). The data suggest that transcriptional (Figures 3b and d) .
To evaluate protective tumor immunity induced by this DNA vaccine strategy, mice were immunized once by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA or related control vectors. After day 14, these mice were challenged with B16OVA. CMV-OVAhsp70-CD11c DNA vaccine generated tumor protection when compared with CMV-OVA-CD11c-IL-15 or CMV-hsp70-CD11c-IL-15 DNA vaccine (Figure 4a ). However, CMV-OVAhsp70-CD11c-IL-15 DNA vaccine elicited better tumor protection than CMV-OVAhsp70-CD11c DNA vaccine (Po0.05) (Figure 4a ). Moreover, CMV-OVAhsp70-CD11c-IL-15 DNA vaccine also generated long-lasting tumor protection (tumor challenge at day 40 post DNA immunization) (Figure 4c ). The data show that transcriptional IL-15-directed in vivo DC targeting enhances OVAhsp70 DNA vaccine-elicited long-lasting Th1 and CTL responses and tumor protection.
CD8T cell-mediated primary tumor protection elicited by this DNA vaccine strategy is DC or CD4T cell dependent during the induction phase of immune responses
To dissect the cellular mechanisms underlying this DNA vaccine strategy, endogenous DC or CD4T cells were depleted during immunization and CD8T cells were depleted during tumor challenge (day 14 after CD8T cell-dependent long-lasting tumor protection can be elicited by this DNA vaccine strategy in both normal and CD4T cell deficient mice
To further examine the function of T cells in long-lasting tumor protection elicited by this DNA vaccine strategy, CD4T cells were depleted during immunization and CD8T cells were depleted during tumor challenge (day 40 post immunization). CD4T cell depletion did not diminish, but slightly increased long-lasting tumor protection elicited by CMV-OVAhsp70-CD11c-IL-15 DNA vaccine (Figure 4c ). However, CD8T cells were absolutely required to clear tumor cells (Figure 4c ). This data indicates that CD8T cell-dependent long-lasting tumor protection can be elicited by this DNA vaccine strategy in both normal and CD4T cell deficient mice.
In -c) . Importantly, as shown in Figure 5d , DC-derived, not epidermal cell-derived, IL-15 was able to promote tumor protection. The data suggest that in vivo DCderived IL-15 is important to enhance immune responses and tumor protection.
Transcriptional IL-15-directed in vivo DC targeting DNA vaccine is effective in a clinically relevant B16 melanoma model
To test whether this novel DNA vaccine strategy can be effective in a murine B16 melanoma using the self/tumor Ag (TRP2), mice were immunized by Gene Gun with CMV-TRP2-CD11c-IL-15, CMV-TRP2hsp70-CD11c or CMV-TRP2hsp70-CD11c-IL-15 DNA on days 1, 7 and 14. On day 21, these mice were challenged with B16. Consistent with earlier report, 7 mice immunized with CMV-TRP2hsp70-CD11c DNA showed longer survival when compared with CMV-TRP2-CD11c-IL-15 DNA (Po0.05).
However, CMV-TRP2hsp70-CD11c-IL-15 DNA vaccine was much more effective in eliciting tumor protection than CMV-TRP2hsp70-CD11c DNA vaccine (Po0.005) ( Figure 6 ). This data suggests that transcriptional IL-15-directed in vivo DC targeting DNA vaccine is effective in a self/tumor Ag (TRP2) B16 melanoma model, implying that this novel strategy might be translatable into a clinically relevant setting. Transcriptional
Discussion
There is currently much interest in exploring in vivo DC targeting DNA vaccine strategies, which may provide a practical way to develop bulk quantities of effective vaccines for cancer and infectious diseases. 18, 19, 22 IL-15, which was ranked number one in NCI Immunotherapy Agent Workshop Proceedings, has been tested to enhance the effects of tumor vaccine, chemotherapy or adoptive cell transfer and HIV-1 vaccine. [35] [36] [37] However, IL-15 has a short half-life and high doses are needed to achieve biological responses in vivo. DNA-delivered IL-15 has been shown to increase the magnitude of the response to DNA vaccines. 36, 37 Also, DC-derived IL-15 may serve as a signal for DC activation and maturation to promote immunity. 35, [38] [39] [40] It is unknown whether transcriptional IL-15-directed in vivo DC targeting can greatly enhance the efficacy of DNA vaccines.
DC-specific CD11c promoter-driven Ag expression is insufficient to elicit optimal T-cell immunity; 41 therefore, the ubiquitous expression and secretion of Aghsp70 by mammalian cells was designed. Although IL-15 mRNA was found in various cell populations, IL-15 protein is secreted at very low levels and is not easily detectable under physiological conditions. 42 Furthermore, DC-derived IL-15 may have some unique abilities to its biological functions. 39, 43, 44 Therefore, the restricted expression and secretion of IL-15 by DC was designed. 45 Also, DC-derived IL-15 is involved in the resistance to DC maturation-accompanied apoptosis in vitro. 46 In this study, transcriptional IL-15-directed DC targeting increased the levels of CD80 and CD86 on DC (Figure 2a) , suggesting an enhanced DC ability to stimulate T cells. DC present IL-15 in trans to CD8T cells and NK cells through IL-15Ra binding IL-15. 47, 48 Transcriptional IL-15-directed DC targeting increased the expression of IL-15Ra on DC (Figure 2a) , suggesting an enhanced DC ability to promote T-and/or NK-cell immunity. Furthermore, transcriptional IL-15-directed DC targeting increased the productions of IL-6, IL-12 and TNF-a by DC (Figure 2b ). This further suggests that transcriptional IL-15-directed DC targeting might modulate DC activation. In this study, BM-derived DC were generated in the presence of mouse GM-CSF and IL-4 and purified immature CD11c + DC were transfected by DNA encoding Aghsp70 and IL-15. However, some earlier reports have indicated that DC can be produced by the direct action of IL-15 on precursor cells. 38, [49] [50] [51] [52] [53] [54] Whether DC precursors transfected by DNA encoding Aghsp70 and IL-15 in the presence or absence of mouse GM-CSF and/ or IL-4 can influence DC activation needs to be further investigated in future studies.
After immunization, DNA-engineered DC or other cells produce, secrete and process Aghsp70. Soluble unprocessed Aghsp70 drains to lymph nodes in which resident DC process and present it to naïve T cells. A second wave of OVAhsp70 reaches the lymph nodes later by an influx of transfected Aghsp70-bearing DC from the skin, which is required for the effective T-cell priming. Transcriptional IL-15-directed DC targeting elevated the level of CCR7 on DC (Figure 2a ). This indicates that DC engineered by Aghsp70 and IL-15 may be effective in migration to lymph nodes for potent T-cell priming. 55 However, whether IL-15-targeted Aghsp70-bearing DC are primed with targeted Aghsp70 in skin or in draining lymph nodes is unclear. It should be established in future studies.
One major goal of vaccine strategies is to elicit Agspecific CD4T cells, which are important to generate persisting Ag-specific memory CTL. [56] [57] [58] Transcriptional IL-15-directed in vivo DC targeting DNA vaccine encoding OVAhsp70 elicited strong long-lasting OVA-specific IFN-g-producing CD4T cell responses (these cells did not produce IL-4 or IL-15 on in vitro restimulation, data not shown) (Figures 3a and c) . Therefore, it is not surprising that this DNA vaccine strategy also elicited long-lasting CTL responses (Figures 3b and d) and, more importantly, effective tumor protection (Figure 4a ). The induction of strong protective Th1 and CTL responses may be associated with the in vivo activation of a minute subset of DC. The precise DC subpopulations that are targeted by IL-15 in this strategy need to be further delineated.
It has been shown that IL-15 codelivered with vaccines overcomes CD4T cell deficiency for promoting CD8T cells and DC-derived IL-15 during priming is also necessary for optimal induction of long-lasting CD8T cells even in the presence of CD4T cell helpers. 44 In this DNA vaccine strategy, even though CD4T cell depletion during immunization abrogated CD8T cell-mediated primary tumor protection (Figure 4b) , an effective CD8T cell-dependent long-lasting tumor protection was generated in both normal and CD4T cell deficient mice (Figure 4c ). This suggests that transcriptional IL-15-directed in vivo DC targeting may be important to immunize CD4T cell deficient individual for an effective long-lasting CTL-based protection.
DC and other skin cells such as epidermal cells transfected by DNA encoding Aghsp70 and IL-15 produce and secrete these molecules. Overexpression of IL-15 in the epidermis promotes cutaneous immunity. 59 It was assumed that epidermal cell-derived IL-15 may improve Aghsp70-bearing DC function through a paracrine manner, thereby eliciting the enhanced Ag-specific immune responses and antitumor immunity. However, DC-derived, not epidermal cell-derived, IL-15 improved cellular and humoral immune responses and tumor protection in this DNA vaccine ( Figure 5 ). This suggests that DC-derived IL-15 may modulate DC through an autocrine manner to elicit the optimal immune responses and protective immunity. However, we could not rule out the possibility that the enhanced immune responses and antitumor immunity might be due to the difference in the amount of IL-15 produced at the vaccination site.
Regardless of the precise mechanism(s), this observation emphasizes the importance of DC as the resource of IL-15 in DNA vaccinations. We were not able to examine whether IL-15 produced by in vivo DNA vaccineengineered DC is sufficient to enhance the potency of DNA vaccine using IL-15 À/À mice because of the concern that IL15 À/À mice lack NK cells and have marked Transcriptional IL-15-directed in vivo DC targeting DNA vaccine S Tian et al reductions in memory CD8T cells, NK1.1 T cells, Thy1-CD8a intraepithelial lymphocytes and abnormal development of DC from early ontogeny. 53, 60 Obviously, the use of OVA model Ag in C57BL/B6 mice cannot properly predict the possibility of this DNA vaccine strategy in a clinically relevant setting. 19 To create an effective DNA vaccine with the possible potential clinical applicability, we tested the efficacy of protective tumor immunity elicited by this DNA vaccine strategy in a clinically relevant B16 melanoma using the self/tumor Ag (TRP2). Transcriptional IL-15-directed in vivo DC targeting greatly enhanced the TRP2hsp70 DNA vaccine-elicited tumor protection in a clinically relevant B16 melanoma model (Po0.005) (Figure 6 ). Likely, this novel DNA vaccine strategy can be translated into a clinically relevant setting.
The data suggest that transcriptional IL-15-directed in vivo DC targeting enhanced the efficacy of DNA vaccine encoding Aghsp70, but not Ag alone (Figures 2-4, 6 ). Persistent Ag delivery and stabilization of Ag presentation may be an important consequence of DC activation in vivo.
61 It is, therefore, possible that the expression, secretion and processing and presentation of Aghsp70 by DNA-engineered DC may be important to collaborate with DC-derived IL-15 for optimal improvement of DC activation and inducing T-cell immunity. The precise mechanisms need to be investigated in future studies. Furthermore, because enhancements in immunity to tumors are mediated by breaking tolerance to selfAg, the immunity to the coexpressed IL-15, which is a 'self-Ag', and the potential consequences for clinical applications are worthwhile to be addressed in future studies.
In summary, we showed the proof-of-concept of a novel transcriptional IL-15-directed in vivo DC targeting DNA vaccine that improves DC activation, elicits longlasting Ag-specific Th1 and CTL responses and tumor protection, generates CD8T cell-dependent long-lasting protective immunity in both normal and CD4 deficient mice and is effective in a clinically relevant tumor model. These findings will be important for developing next generation vaccines against cancers and viral infections in both healthy and CD4 deficient individuals.
Materials and methods
Mice and cell lines
C57BL/B6 and CD11c-DTR (B6.FVB-Tg(Itgax-DTR/EGF-P)57Lan/J) mice (female, 6-8 weeks) were purchased from Taconic (Germantown, NY, USA) and JAX (Bar Harbor, ME, USA), and housed in specific pathogen-free conditions in the University of Pittsburgh animal facility. All animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. Murine melanoma tumor cell B16OVA (a gift from Drs E Lord and J Frelinger at University of Rochester, Rochester, NY, USA) 62 or B16 (ATCC, Manassas, VA, USA) was maintained in DMEM (IRVINE Scientific, Santa Ana, CA, USA) supplemented with 10% FBS (Hyclone, Logan, UT, USA), 2 mM glutamine (Invitrogen, Carlsbad, CA, USA) and 1 Â antibiotic antimycotic solution (Sigma, St Louis, MO, USA).
Vector constructions
Restricted enzymes, T4 DNA ligase and antarctic phosphatase were purchased from NEB (Beverly, MA, USA). AccuPrime pfx DNA polymerase and one shot Top10 chemically competent Escherichia coli were purchased from Invitrogen. All primers were synthesized by IDTDNA (Coralville, IA, USA). Detailed vector construction is described in supplemental materials. Briefly, pcDNA3.1 (+) (Invitrogen) was digested with EcoRV and Bst1107I and self-ligated with T4 DNA Ligase (resultant vector 1). PCR-amplified NheI and XhoIdigested BGHpA was cloned into NheI and XhoI-digested vector 1 (resultant vector 2). NotI and XhoI-digested CD11c-Ea d fragment (CD11c-pDOI-5 vector is a gift from Dr T Brocker at Ludwig-Maximilians-Universitat Munchen, Germany) was cloned into NotI and XhoI-digested vector 2 (resultant vector 3: CMV-AscI-CD11c-EcoRI). OVA, hsp70 or OVAhsp70 was cloned into AscI-digested vector 3 (resultants CMV-OVACD11c, CMV-hsp70-CD11c and CMV-OVAhsp70-CD11c). PCR-amplified EcoRI-digested optimized human IL-15 36 (human IL-15 cDNA is a gift from Dr TA Waldmann at NIH, Bethesda, MD, USA) was cloned into EcoRIdigested CMV-OVA-CD11c, CMV-hsp70-CD11c or CMVOVAhsp70-CD11c (resultants CMV-OVA-CD11c-IL-15, CMV-hsp70-CD11c-IL-15 or CMV-OVAhsp70-CD11c-IL-15). PCR-amplified blunt end fragment of epidermal keratin K14-EcoRI-BGHpA (K14) 63 was cloned into pCRBlunt II-TOPO (Invitrogen) (resultant vector 4). NotI and XhoI-digested K14 was cloned into NotI and XhoIdigested CMV-OVAhsp70-CD11c vector (resultant CMVOVAhsp70-K14). EcoRI-digested optimized human IL-15 was cloned into EcoR I-digested CMV-OVAhsp70-K14 (resultant CMV-OVAhsp70-K14-IL-15). PCR-amplified AscI-digested TRP2 or TRP2hsp70 7 was cloned into AscI-digested CMV-OVA-CD11c or CMV-OVA-CD11c-IL- 15 (resultants CMV-TRP2-CD11c-IL-15, CMVTRP2hsp70-CD11c or CMV-TRP2hsp70-CD11c-IL-15). Inserted genes were confirmed by both enzyme digestion and DNA sequencing. DNA was purified using EndoFree plasmid kits (Qiagen, Valencia, CA, USA).
In vitro DC transfection and assays
Bone marrow-derived DC were generated as described earlier. 64 Briefly, bone marrow cells (1 Â 10 6 per ml) taken from naïve C57BL/B6 mice were cultured in RPMI1640 (IRVINE Scientific) supplemented with 10% FBS (Hyclone), 2 mM glutamine (Invitrogen), 1 Â antibiotic antimycotic solution (Sigma), recombinant mouse GM-CSF (1000 unites per ml) and IL-4 (1000 unites per ml) (R&D Systems, Minnneapolis, MN, USA). On days 5-6 of DC culture, CD11c + DC were purified using anti-CD11c micro-beads (Miltenyi Biotec., Auburn, CA, USA). CD11c + DC (1 Â 10 6 ) in 40 ml medium in a 12-well plate were shot with a bullet (3 mg DNA/bullet) using a Gene Gun (Bio-Rad, Hercules, CA, USA) at 260 psi pressure as described in Larregina et al. 65 After transfection, cells were continually cultured in 1 ml BM-DC culture medium for 2 or 3 days. Day 2 post transfection, the pooled DC culture supernatant (3 ml) was harvested and concentrated to 300 ml using a Centricon-10 (Amicon Millipore, Billerica, MA, USA) after the vendor's instruction. The concentration of human IL-15 in concentrated supernatants was determined by human 31 OVAhsp70 in DC lysates or 293T cell supernatants was detected by western blotting using mouse anti-human hsp70 mAb (Assay Designs Stressgene, Ann Arbor, MI, USA) as described earlier. 31 Day 3 post transfection, culture supernatants and DC were harvested. The concentration of IL-6, IL-12p40 or TNF-a in DC culture supernatants was determined by ELISA kits (eBioscience and Biolegend, San Diego, CA, USA). To examine DC phenotypes, harvested DC were incubated with anti-mouse CD16/32 (eBioscience), and then stained with APC-anti-mouse CD11c (HL3), PE-antimouse CD86 (GL1), PE-anti-mouse CD80 (16-10A1), PE-anti-mouse CCR7 (4B12) or FITC-anti-mouse IL-15Ra (isotype control of each antibody was used in control staining) (eBioscience; R&D Systems; BD Biosciences), and analyzed by flow cytometry on a BD LSRII with CellQuest software (BD Biosciences). The flow cytometric data were analyzed using Flowjo software (Tree star, Ashland, OR, USA).
CD4T cell responses
C57BL/B6 mice (three mice/group) were immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA and related control vectors once (3 mg DNA/bullet, four bullets at four sites, 400 psi pressure) as described in Condon et al.
14 Day 14 or 40 post immunization, CD4T cells were isolated from splenocytes using anti-mouse CD4 micro-beads (Miltenyi Biotec.). Isolated CD4T cells (6 Â 10 6 ) were cultured with OVA-specific MHC class II peptides (OVA 323À339 , purity495%, synthesized and HPLC purified in the core facility of University of Pittsburgh) (200 ng ml In vivo killing assays C57BL/B6 mice (three mice/group) were immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA and related control vectors once as described above. Day 14 post immunization, naive syngeneic splenocytes were labeled with either 0.5 or 5 mM CFSE (Molecular Probes, Eugene, OR, USA) for 10 min at 37 1C, washed and then pulsed for 1 h with OVA-specific MHC class I peptides (OVA 257À264 , 200 ng ml -1 , purity495%, synthesized and HPLC purified in the core facility of University of Pittsburgh). Labeled and pulsed cells were subsequently mixed at a 1:1 ratio and approximately 10 7 cells were injected intravenously into immunized mice. After 12 h, mice were killed and splenocytes were analyzed by flow cytometry as described above. The percentage of OVAspecific lysis was calculated as follows: % specific lysis ¼ (1À((ratio of CFSE lo /CFSE hi in naive mice)/(ratio of CFSE lo /CFSE hi in immunized mice))) Â 100.
In vitro killing assays C57BL/B6 mice (three mice/group) were immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA and related control vectors once as described above. Day 40 post immunization, splenocytes (6 Â 10 6 per ml) were cultured with OVA 257À264 peptides (200 ng ml -1 ) at 37 1C, 5% CO 2 for 48 h. To quantify the target-cell killing activity mediated by OVA-specific T lymphocytes, the flow cytometry-based CTL assay (Cytoxilux, OncoImmunin, Inc., Gaithersburg, MD, USA) was used to detect the specific cleaved caspase in the target cells according to vendor's protocol. Briefly, 4 Â 10 6 B16OVA (target cells) in 2 ml culture medium were cultured with OVA 257À264 peptides (200 ng ml -1 ) at 37 1C, 5% CO 2 . After 45 min, TFL4 (2 ml) was added and B16OVA cells were continually cultured for 15 min. The target cells were then washed with serum-free RPMI and resuspended in wash buffer at 2 Â 10 6 per ml. Target cells (T) (2 Â 10 5 per well) were mixed with titrated lymphocyte effectors (E) at ratios of 50:1, 25:1 or 12.5:1 (E:T) in 96-well plates in 200 ml wash buffer. The cell mixture was centrifuged at 1400 rpm for 5 min at room temperature. Cell pellets were resuspended in 75 ml caspase substrate solution and incubated at 37 1C, 5% CO 2 for 2 h. The caspase activity in target cells was analyzed by flow cytometry.
Antibody responses
C57BL/B6 mice (two mice/group) were immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 or CMV-OVAhsp70-K14-IL-15 DNA once as described above on day 1. Sera were collected on days 21, 28, 35 and 42. Anti-OVA Ig was monitored by standard ELISA. Briefly, 96-well plate was coated with OVA protein (Grade V, Sigma) in carbonate buffer (PH9.5) (10 mg ml -1 ) at 4 1C overnight. Samples of sera were diluted 10 times in 10% FCS and added into OVA-coated well for incubation for 2 h at room temperature. After extensive washing with wash buffer, HRP-goat anti-mouse Ig (Millipore) was added for incubation for 1 h at room temperature. After extensive washing with wash buffer, substrates of HRP were added and plates were placed in the dark. After 15 min, the plate was read by an ELISA reader SpectraMax (Molecular Devices, Sunnyvale, CA, USA) at OD450.
Tumor protection
C57BL/B6 mice (3-5 mice/group) were immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA and related control vectors once as described above on day 1. Day 14 or 40 post immunization, mice were challenged subcutaneously. with B16OVA (1 Â 10 5 ). In some experiments, mice were immunized by Gene Gun with CMV-TRP2hsp70-CD11c-IL-15 DNA and related control vectors as described above on days 1, 7 and 14. On day 21, mice were challenged subcutaneously with B16 (5 Â 10 4 ). Tumors were measured using a digital slide calipers (Fisher Scientific, Pittsburgh, PA, USA) in the two perpendicular diameters every 3 days. Mice were sacrificed when tumor reached 10 mm in mean diameter. To transiently deplete endogenous CD11c + DC, CD11c-DTR transgenic mice were injected intraperitoneally once with diphtheria toxin (Sigma) at 5 ng g -1 mouse body weight. 66 After 16-18 h, these mice were immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA as described above. To deplete CD4T cells during immunization, mice immunized by Gene Gun with CMVOVAhsp70-CD11c-IL-15 DNA on day 1 were injected intraperitoneally with anti-mouse CD4 mAb (GK1.5) (200 mg per injection) on days À3, 2 and 5. To deplete CD8T cells during tumor challenge, mice immunized by Gene Gun with CMV-OVAhsp70-CD11c-IL-15 DNA on day 1 were injected intraperitoneally with anti-mouse 
